Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

5.830 +0.130 (+2.28%)
Streaming Delayed Price Updated: 3:44 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Uniqure Ord Shs

< Previous 1 2 3 4 5 6 Next >
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
Recap: uniQure Q4 Earnings
Via Benzinga
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Are UniQure Shares Surging Today?
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's... 
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
S&P 500 Edges Higher; Indivior Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Soligenix Shares Surge
Via Benzinga
Exposures Fossil Fuels
Why UniQure Stock Is Soaring
UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's... 
Via Benzinga
MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing
Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing. 
Via InvestorPlace
Why Is uniQure (QURE) Stock Up 51% Today?
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate. 
Via InvestorPlace
Dow Falls Over 50 Points; US Small Business Optimism Surges In June
Via Benzinga
Topics Stocks
Exposures US Equities
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024
QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
Exposures Product Safety
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.